Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Supreme Court Nominees Should Disclose Views On Constitutional Issues, USA Today Opinion Piece States
One thing that "has been conspicuously absent" from the confirmation hearings for Supreme Court nominee Sonia Sotomayor is "substance," Jonathan Turley, the Shapiro Professor of Public Interest Law at George Washington University, writes in a USA Today opinion piece. According to Turley, "The vast majority of questions and answers remained on a shallow and predictable level where Sotomayor did little more than describe current doctrines and case law -- avoiding disclosures of her own views." He continues, "What is most striking is how Sotomayor"s statements were virtually identical to both her conservative and liberal predecessors," including her comments that Roe v. Wade and Planned Parenthood v. Casey are "the precedent of the court."Turley writes, "The content-light character in these hearings is largely the product of the "Ginsburg rule" -- named after Justice Ruth Bader Ginsburg, who refused to answer questions in her 1993 confirmation hearing about any case or matter upon which she might later vote." According to Turley, "Later nominees for both parties have relied on the Ginsburg rule to turn the hearings into prolonged photo-ops for senators, who largely ask wafer-thin questions to solicit largely scripted answers." The rule "allows nominees to get by with meaningless sound bites that promise to respect precedent, the Framers [of the Constitution] and collegiality in general," he adds. Furthermore, it "tells the public nothing about a nominee"s philosophy or purpose before giving her life tenure on the world"s most powerful court," Turley writes.According to Turley, there is a "simple solution to returning substance to the confirmation process: End the Ginsburg rule by insisting that nominees answer questions about their specific views on constitutional rights." Although "the current system works well for presidents, nominees and senators," it "does little for the public or the system of justice," he writes (Turley, USA Today, 7/16).
generic viagra online
ExonHit Announces Last Patient Out For EHT 0202 Phase IIa Study In Alzheimer's
ExonHit Therapeutics (Paris:ALEHT) announced that clinical testing of EHT 0202, its lead therapeutic compound in Alzheimer"s disease, is progressing well. Final patient dosing for the Phase IIa proof-of-concept clinical trial assessing EHT 0202 in patients with Alzheimer"s disease is completed.
News of the day
What Is Cervical Cancer? What Causes Cervical Cancer?
Cervical cancer, or cancer of the cervix, is cancer of the entrance to the uterus (womb). The cervix is the narrow part of the lower uterus, often referred to as the neck of the womb. Cervical cancer occurs most commonly in women over the age of 30.
Public Health

Cotton-Seed Based Drug Shows Promise In Treating Severe Brain Cancer

An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB). The new results are from a Phase II clinical trial of AT-101, a pill manufactured from a potent compound in cottonseed that overcomes the abnormal growth patterns of tumor cells. This cottonseed-based agent must be properly dosed and monitored by physicians. In clinical tests, AT-101 halted the cancer"s progression in many of the 56 patients, said John Fiveash, M.D., an associate professor in the UAB Department of Radiation Oncology and the lead researcher on the new study. Despite undergoing other treatments, including surgery, chemotherapy and radiation, the trial patients" brain cancer had begun to grow again prior to starting AT-101 treatments. The trial-monitored patients took only AT-101 daily for three out of four weeks. Glioblastomas are more common in adults and are considered fast-growing brain tumors that are very difficult to treat, Fiveash said. "After getting this drug some of these patients went many months without any new growth in their tumors," Fiveash said. "We are able to do that with a well-tolerated oral medication, and that is a major benefit." His initial results will be presented May 30 during the poster discussion of central nervous system tumors at the American Society for Clinical Oncology annual meeting in Orlando, Fla. Fiveash said the drug would likely work best in combination with radiation and chemotherapy to boost the cancer-fighting properties of those treatments. Also, investigators are trying to learn which patients are most likely to benefit from AT-101. The AT-101 trial is a partnership that includes Fiveash, the UAB Comprehensive Cancer Center, Massachusetts General Hospital in Boston, Johns Hopkins University in Baltimore, The Cleveland Clinic in Ohio, Henry Ford Hospital in Detroit, Emory University in Atlanta, Moffit Cancer Center in Tampa, the University of Pennsylvania in Philadelphia, Wake Forest University in Winston-Salem, N.C., and the National Cancer Institute"s Cancer Therapeutics Evaluation Program. AT 101 is manufactured by Ascenta Therapeutics Inc. based in Malvern, Penn. Multiple preclinical and clinical trials with AT-101 are ongoing in several tumor types, including prostate, lung, B-cell malignancies and other forms of cancer. About UAB The UAB Comprehensive Cancer Center is the only one in a five-state region to have the National Cancer Institute"s comprehensive designation. The center collaborates with the UAB Department of Radiation Oncology and other divisions to remain a world leader in groundbreaking translational research and leading-edge patient care. About Ascenta Therapeutics Ascenta Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The lead agent, AT-101, is an orally active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials. The company"s preclinical pipeline includes the oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program. University of Alabama at Birmingham


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009